Search studies using keywords
5,026 Studies in the database containing data with -log p ≥ 0 (showing 1-20)
Pages: 1 2 3 4 5 6 7 8 9 10 >>
No data sets (in No Studies) added to Browser
Identifier Name Phenotype(s) Total p-values Related citationsAdd data sets to Browser Related data
HGVST5022 plus GWAS of Left atrial volume and function 
  • Left atrial minimum volume
  • Left atrial passive emptying fraction
  • Left atrial active emptying fraction
  • Left atrial maximum volume
  • Left atrial total emptying fraction
18
HGVST5023 plus GWAS of Alcohol-related cirrhosis 
  • Aspartate aminotransferase platelet ratio index in high alcohol intake
  • Fibrosis-4 index in high alcohol intake
  • Forns index in high alcohol intake
  • Alanine transaminase levels in high alcohol intake
  • Aspartate transaminase levels in high alcohol intake
161
HGVST5024 plus GWAS of Fasting glucose and insulin 
  • Fasting insulin
  • Fasting glucose
125
HGVST5025 plus GWAS of Lupus nephritis 
  • Lupus nephritis in systemic lupus erythematosus
1
HGVST5026 plus GWAS of Kidney function 
  • Vegetable consumption
8
HGVST5027 plus GWAS of Hand, foot, and mouth disease 
  • CV-A6-associated hand, foot, and mouth disease (severe vs mild)
6
HGVST5018 plus GWAS of Inflammatory proteins 
  • CCL23 levels
  • Cystatin D levels
  • interleukin 15 receptor subunit alpha levels
  • Tumor necrosis factor ligand superfamily member 12 levels
  • CD6 levels
  • CCL25 levels
  • Fibroblast growth factor 5 levels
  • Interleukin-12 subunit B levels
  • interleukin-18 receptor 1 levels
  • CD40 levels
  • Tumor necrosis factor beta levels
  • Matrix metalloproteinase levels
  • Interleukin-10 receptor B levels
  • Adenosine Deaminase levels
  • Monocyte chemoattractant protein-4 levels
  • Matrix metalloproteinase-10 levels
  • CXCL6 levels
22
HGVST5019 plus GWAS of Cancer 
  • Cancer
  • Colorectal cancer
  • Epithelial ovarian cancer
  • Chronic lymphocytic leukemia
  • Non-melanoma skin cancer
  • Melanoma
  • Pancreatic cancer
  • Prostate cancer
  • Breast cancer
  • Lung cancer
525
HGVST5020 plus GWAS of Externalizing behaviours 
  • Externalizing behaviour score
5
HGVST5021 plus GWAS of Chronic lymphocytic leukemia 
  • Chronic lymphocytic leukemia (time to first treatment)
2
HGVST5014 plus GWAS of Response to clopidogrel treatment 
  • Cardiovascular death, myocardial infarction or stroke in response to clopidogrel treatment
  • Cardiovascular death or myocardial infarction in response to clopidogrel treatment
  • Platelet reactivity in response to clopidogrel treatment
  • Stent thrombosis in response to clopidogrel treatment
41
HGVST5015 plus GWAS of Circulating cytokines 
  • IgA levels
  • Interleukin-18 levels
  • C-reactive protein levels
  • Thymus and reactivation regulated chemokine levels
  • S100 calcium-binding protein levels
  • Monocyte chemoattractant protein-1 levels
  • Erythropoietin levels
  • Vascular endothelial growth factor A levels
28
HGVST5016 plus GWAS of Response to tofacitinib treatment 
  • Response to tofacitinib treatment (herpes zoster)(time to event)
  • Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)
  • Response to tofacitinib treatment (herpes zoster)
  • Response to tofacitinib treatment in rheumatoid arthritis (herpes zoster)(time to event)
  • Response to tofacitinib treatment in psoriasis (herpes zoster)
  • Response to tofacitinib treatment in psoriasis (herpes zoster)(time to event)
25
HGVST5017 plus GWAS of Keratoconus 
  • Keratoconus
36
HGVST5010 plus GWAS of Sun-seeking behavior 
  • Sun-seeking behavior
5
HGVST5011 plus GWAS of Age-related hearing impairment 
  • Age-related hearing impairment
47
HGVST5012 plus GWAS of Preeclampsia 
  • Preeclampsia
16
HGVST5013 plus GWAS of Breast cancer-specific survival 
  • 15-year breast cancer-specific survival (ER negative treated with chemotherapy)
  • 15-year breast cancer-specific survival (ER positive or PR positive, and HER2 negative treated with chemotherapy)
  • 15-year breast cancer-specific survival (ER positive treated with endocrine therapy)
  • 5-year breast cancer-specific survival (treated with tamoxifen)
  • 15-year breast cancer-specific survival (grade 3 tumor)
  • 15-year breast cancer-specific survival (treated with anthracyclines)
  • 5-year breast cancer-specific survival (ER negative treated with chemotherapy)
  • 15-year breast cancer-specific survival (ER positive, PR positive, and HER2 negative)
10
HGVST5006 plus GWAS of Tau deposition 
  • Tau burden
12
HGVST5007 plus GWAS of Acute respiratory distress syndrome 
  • Acute respiratory distress syndrome
2